Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
NSL literature pointer PMID 8004884 L-Carnitine laboratory index [PMID: 8004884] National Science Labs indexing note for PMID 8004884: review the PubMed methods, models, and limitations before citing
One study included people who were being treated for obstructive sleep apnea with a continuous positive airway pressure (CPAP) machine
No cardiovascular risks: The hypertension and cardiovascular events associated with EPO don't occur with ARA-290 because the pathways responsible aren't activated
US$ 14997.50
Sold : Login>>
